James Parsons
Vermogen: 786 958 $ op 31-10-2026
Vermogen: 786 958 $ op 31-10-2026
James T.
Parsons is currently Chairman at DiaMedica Therapeutics, Inc. since 2025, Independent Director at Oncolytics Biotech, Inc. since 2022, and Chief Financial Officer at Sernova Biotherapeutics, Inc. starting in 2025.
Former roles include Director at YM BioSciences, Inc., Vice President-Finance & Administration at Aptose Biosciences, Inc. from 2000 to 2003, Controller & Assistant Treasurer at Timminco Ltd. from 1995 to 2000, Chief Financial & Accounting Officer at Trillium Therapeutics, Inc. from 2011 to 2021, Chief Financial Officer at ProMIS Neurosciences, Inc. from 2005 to 2010, and Chief Financial Officer & Secretary at Trillium Therapeutics, Inc. from 2011 to 2014.
Education includes graduate studies at The University of Waterloo.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 01-06-2026 | 75.854 ( -.--% ) | 701 650 $ | 31-10-2026 | |
| 14-04-2026 | 614.605 ( 0,16% ) | 46 710 $ | 31-10-2026 | |
| 01-06-2026 | 2.250 ( 0% ) | 20 813 $ | 31-10-2026 | |
| 22-09-2026 | 41.849 ( 0,03% ) | 17 786 $ | 31-10-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| DIAMEDICA THERAPEUTICS INC. | Voorzitter | 01-01-2025 |
| SERNOVA BIOTHERAPEUTICS INC | Financieel Directeur/CFO | 07-10-2024 |
| ONCOLYTICS BIOTECH INC. | Directeur/Bestuurslid | 16-06-2022 |
| Bedrijven | Functie | Einde |
|---|---|---|
| TRILLIUM THERAPEUTICS | Financieel Directeur/CFO | 17-11-2021 |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Provides research and development of pharmaceuticals | Financieel Directeur/CFO | 06-06-2014 |
| PROMIS NEUROSCIENCES, INC. | Financieel Directeur/CFO | 20-10-2010 |
| APTOSE BIOSCIENCES INC. | Financieel Directeur/CFO | 01-01-2003 |
| TIMMINCO LIMITED | Comptroller/Controller/Auditor | 01-01-2000 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 10 |
|---|---|
Aptose Biosciences, Inc.
Aptose Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Discovers, research and develops anticancer therapies with high safety profiles | Health Technology |
Oncolytics Biotech, Inc.
Oncolytics Biotech, Inc. BiotechnologyHealth Technology Discovers and develops pharmaceutical products for the treatment of cancers | Health Technology |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Produces cancer-related drug products | Health Technology |
Sernova Biotherapeutics, Inc.
Sernova Biotherapeutics, Inc. BiotechnologyHealth Technology Develops life science products | Health Technology |
Timminco Ltd.
Timminco Ltd. Metal FabricationProducer Manufacturing Manufactures specialty magnesium, calcium and strontium alloys | Producer Manufacturing |
Trillium Therapeutics, Inc.
Trillium Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Researches, develops and manufactures medicines & therapies for cancer | Health Technology |
DiaMedica Therapeutics, Inc.
DiaMedica Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that engages in development and commercialization of therapeutic treatments from novel recombinant proteins | Health Technology |
ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. BiotechnologyHealth Technology Discovers and develops precision medicine solutions for the treatment of neurodegenerative & misfolded protein diseases | Health Technology |
The University of Waterloo
The University of Waterloo Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Provides research and development of pharmaceuticals | Commercial Services |
Kies jouw editie
Alle financiële informatie op nationaal niveau